Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Nasim Mavaddat, Daniel Barrowdale, Irene L. Andrulis, Susan M. Domchek, Diana Eccles, Heli Nevanlinna, Susan J. Ramus, Amanda Spurdle, Mark Robson, Mark Sherman, Anna Marie Mulligan, Fergus J. Couch, Christoph Engel, Lesley McGuffog, Sue Healey, Olga M. Sinilnikova, Melissa C. Southey, Mary Beth Terry, David Goldgar, Frances O'MalleyEsther M. John, Ramunas Janavicius, Laima Tihomirova, Thomas V. O. Hansen, Finn C. Nielsen, Ana Osorio, Alexandra Stavropoulou, Javier Benitez, Siranoush Manoukian, Bernard Peissel, Monica Barile, Sara Volorio, Barbara Pasini, Riccardo Dolcetti, Anna Laura Putignano, Laura Ottini, Paolo Radice, Ute Hamann, Muhammad U. Rashid, Frans B. Hogervorst, Mieke Kriege, Rob B. van der Luijt, Susan Peock, Debra Frost, D. Gareth Evans, Carole Brewer, Lisa Walker, Tuomas Heikkinen, Paivi Heikkila, Kristiina Aittomaki, EMBRACE, Consortium Investigators Modifiers, SWE-BRCA Collaborators, HEBON, kConFab Investigators, GEMO Study Collaborators

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalCancer Epidemiology, Biomarkers & Prevention
Volume21
Issue number1
Pages (from-to)134-147
Number of pages14
ISSN1055-9965
DOIs
Publication statusPublished - 2012
MoE publication typeA1 Journal article-refereed

Fields of Science

  • ESTROGEN-RECEPTOR STATUS
  • IMMUNOHISTOCHEMICAL MARKERS
  • GERMLINE MUTATIONS
  • TUMOR SUBTYPES
  • FEATURES
  • RISK
  • PHENOTYPE
  • WOMEN
  • PREDICTION
  • CARCINOMA
  • 3123 Gynaecology and paediatrics

Cite this